Page 148 - Genomic Testing News Today

Genetic testing for women with breast cancer is important, as it may help determine the risk of developing secondary primary breast cancer.

Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.

A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.